ArticleBJU international2016

Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.

Marc R Matrana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.